Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).

Autor: Chai, Meng¹ (AUTHOR), He, Yongming² (AUTHOR), Zhao, Wang³ (AUTHOR), Han, Xuebin⁴ (AUTHOR), Zhao, Guoyan⁵ (AUTHOR), Ma, Xueping⁶ (AUTHOR), Qiao, Ping⁷ (AUTHOR), Shi, Dongmei¹ (AUTHOR), Liu, Yuyang¹ (AUTHOR), Han, Wei¹ (AUTHOR), An, Pei⁸ (AUTHOR), Li, Haoyu⁸ (AUTHOR), Yan, Shuling⁸ (AUTHOR), Ma, Qingyang⁸ (AUTHOR), Deng, Huan⁸ (AUTHOR), Qian, Lei⁸ (AUTHOR) cnradium@126.com, Zhou, Yujie¹ (AUTHOR) azzyj12@163.com

Publikováno v: BMC Medicine. 2/28/2023, Vol. 21 Issue 1, p1-11. 11p.

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Autor: Meng Chai, Yongming He, Wang Zhao, Xuebin Han, Guoyan Zhao, Xueping Ma, Ping Qiao, Dongmei Shi, Yuyang Liu, Wei Han, Pei An, Haoyu Li, Shuling Yan, Qingyang Ma, Huan Deng, Lei Qian, Yujie Zhou, on behalf of CREDIT-2 investigators

Publikováno v: BMC Medicine, Vol 21, Iss 1, Pp 1-11 (2023)

Abstract Background Heterozygous familial hypercholesterolemia (HeFH) is largely underdiagnosed and undertreated in China where few patients achieved recommended target levels of low density lipoprotein cholesterol (LDL-C). We conducted the first ran

Externí odkaz: https://doaj.org/article/906517e4ba554bb89dcc632e83d269ce

Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

Autor: Huo, Yong, Chen, Beijian, Lian, Qiufang, Wang, Shuqing, Liu, Lu, Lu, Di, Qu, Yanling, Zheng, Guanzhong, Li, Lipeng, Ji, Yuan, Yin, Guotian, Huang, Wenjun, Xie, Ying, Yang, Xinchun, Gao, Xiufang, An, Pei, Xue, Fengtai, Li, Haoyu, Deng, Huan, Li, Li, Pei, Lijuan, Qian, Lei

Publikováno v: In The Lancet Regional Health - Western Pacific December 2023 41

Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Autor: Qi, Litong, Liu, Dexue, Qu, Yanling, Chen, Beijian, Meng, Haiyan, Zhu, Lei, Li, Lipeng, Wang, Shuqing, Liu, Changyi, Zheng, Guanzhong, Lian, Qiufang, Yin, Guotian, Lv, Lingchun, Lu, Di, Chen, Xiaoshu, Xue, Fengtai, An, Pei, Li, Haoyu, Deng, Huan, Li, Li, Qian, Lei, Huo, Yong

Publikováno v: In JACC: Asia August 2023 3(4):636-645

Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies.

Autor: Qureshi Z; The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Bridgeport, CT., Khanzada M; Department of Internal Medicine, Lahore Medical & Dental College., Safi A; Department of Medicine, Lahore General Hospital., Fatima E; Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan., Altaf F; Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/BronxCare Health System., Vittorio TJ; Department of Internal Medicine, BronxCare Health System, New York, NY.

Publikováno v: Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2024 Mar 12; Vol. 86 (5), pp. 2818-2827. Date of Electronic Publication: 2024 Mar 12 (Print Publication: 2024).